Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single‐Centre Retrospective Study
Endocrinology, Diabetes & Metabolism · 2024
DOI: 10.1002/edm2.489 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2024. Verfasst von Akira Mima und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Osaka Medical and Pharmaceutical University, Osaka, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Dialysis, Glycemic Control. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Tirzepatide is an injectable peptide approved by the US Food and Drug Administration for the treatment of Type 2 diabetes (T2DM). Its weight‐loss effect primarily targets fat reduction; however, such effect on patients with chronic kidney disease (CKD) undergoing haemodialysis (HD) has not been reported.
Methods
Nine patients with CKD undergoing HD received weekly tirzepatide doses (2.5–7.5 mg) once a week. Evaluations encompassed tirzepatide's impact on dry weight (DW) and body composition assessed at baseline and study conclusion using bioelectrical impedance analysis. This longitudinal study included nine patients, with a median age of 53 years and median HD duration of 4 years.
Results
Tirzepatide treatment significantly decreased glycated albumin compared with the value at baseline (22.7 ± 5.4 vs. 18.3 ± 2.5%, p = 0.028, respectively). Significant reductions were observed in DW (−1.0 kg, p = 0.024) and body mass index (−0.6 kg/m 2 , p = 0.050) following tirzepatide administration. Total fat mass was also reduced, but not significantly (− 2.51% from baseline, p = 0.214). In contrast, skeletal muscle mass was not decreased (−1.02% from baseline, p = 0.722). No serious side effects other than nausea were observed during the study period.
Conclusion
Tirzepatide effectively provides good glycaemic control in T2DM patients undergoing HD, decreasing DW by reducing body fat mass without increasing frailty risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Seiwadai Clinic, Nara, Japan.
ORCID-Profile: Akira Mima
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Mima, A., & Horii, Y. (2024). Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single‐Centre Retrospective Study. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.489
Vancouver
Mima A, Horii Y. Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single‐Centre Retrospective Study. Endocrinology, Diabetes & Metabolism. 2024. doi:10.1002/edm2.489
BibTeX
@article{Mima2024,
author = {Mima, Akira and Horii, Yasuhiro},
title = {Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single‐Centre Retrospective Study},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2024},
doi = {10.1002/edm2.489}
}
EUVIMED